0.31%QQQQ 43.45 
0.48%XLF 21.74 3.62%
Digg
Del.icio.us
Newsvine 
Facebook
Stumbleupon
SAN DIEGO - Arena Pharmaceuticals Inc. said Wednesday its first-quarter loss widened on an increase in research and development costs and general and administrative expenses.
| ARNA | 5.8 |  0.03 |
The company reported a loss of $55 million, or 75 cents per share, compared with a loss of $32.4 million, or 53 cents per share, in the prior-year period.
Revenue plunged 47 percent to $2.6 million from $4.9 million in the year-ago period.
Analysts surveyed by Thomson Financial expected a loss of 67 cents per share on revenue of $3 million.
Arena said its research and development costs in the quarter jumped 33 percent to $47.6 million. The company said the increase was due to development of its late-stage obesity drug candidate lorcaserin.
General and administrative costs rose to $8.9 million from $4.9 million.
Shares of Arena fell 6 cents to $5.50 in after-hours trading. The stock earlier finished regular trading unchanged at $5.56.
The above adage is well known by precious-metals investors; in fact I used this quote in one of our monthly reports. I recall how many inquiries ...
India pledged Friday not to engage in a new arms race as talks continued in Vienna over whether to let the U.S. sell India nuclear material and t...
IN THE HEADLINES McCain caps GOP convention vowing 'change is coming' to Washing...
|
Professional Website Design For Corporate - Get a Free Quote Today
Partners  
|
© 2008 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives
EMAIL
PRINT
RSS
SHARE
